HemaCare Corporation reported financial results for the year ended December 31, 2016. For the year, the company’s bioresearch products and services was $13,876,000 against $9,702,000 a year ago. Income from continuing operations before income tax expense was $799,000 against loss from continuing operations before income tax expense of $1,380,000 a year ago. Income from continuing operations, net of taxes was $781,000 against loss from continuing operations, net of taxes of $1,402,000 a year ago. Net income was $781,000 against $3,236,000 a year ago.